Stomach cancer classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:


==Overview==
==Overview==
Gastric cancer can be classified according to the Padova classification system based upon the grade of [[metaplasia]], [[dysplasia]] and invasiveness of the [[disease]]. It may also be classified according to the Japanese classification system based on the type of lesions ([[benign]] or [[malignant]]) and [[atypia]].
[[Gastric cancer]] can be classified according to the Padova [[classification]] [[system]] based upon the grade of [[metaplasia]], [[dysplasia]] and invasiveness of the [[disease]]. It may also be classified according to the Japanese classification system based on the type of [[lesions]] ([[benign]] or [[malignant]]) and [[atypia]].


==Classification==
==Classification==
Gastric cancer can be classified according to the Padova classification system based upon the grade of [[metaplasia]], [[dysplasia]] and invasiveness of the [[disease]]. It may also be classified according to the Japanese classification system based on the type of lesions ([[benign]] or [[malignant]]) and [[atypia]]. The following tables briefly outline the major classification systems:<ref name="pmid10680883">{{cite journal| author=Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K et al.| title=Gastric dysplasia: the Padova international classification. | journal=Am J Surg Pathol | year= 2000 | volume= 24 | issue= 2 | pages= 167-76 | pmid=10680883 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10680883  }}</ref><ref name="pmid27342689">{{cite journal| author=Japanese Gastric Cancer Association| title=Japanese gastric cancer treatment guidelines 2014 (ver. 4). | journal=Gastric Cancer | year= 2017 | volume= 20 | issue= 1 | pages= 1-19 | pmid=27342689 | doi=10.1007/s10120-016-0622-4 | pmc=5215069 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27342689  }}</ref>
[[Gastric cancer]] can be classified according to the Padova [[classification]] [[system]] based upon the grade of [[metaplasia]], [[dysplasia]] and invasiveness of the [[disease]]. It may also be classified according to the Japanese classification system based on the type of [[lesions]] ([[benign]] or [[malignant]]) and [[atypia]]. The following tables briefly outline the major [[classification]] [[systems]]:<ref name="pmid10680883">{{cite journal| author=Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K et al.| title=Gastric dysplasia: the Padova international classification. | journal=Am J Surg Pathol | year= 2000 | volume= 24 | issue= 2 | pages= 167-76 | pmid=10680883 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10680883  }}</ref><ref name="pmid27342689">{{cite journal| author=Japanese Gastric Cancer Association| title=Japanese gastric cancer treatment guidelines 2014 (ver. 4). | journal=Gastric Cancer | year= 2017 | volume= 20 | issue= 1 | pages= 1-19 | pmid=27342689 | doi=10.1007/s10120-016-0622-4 | pmc=5215069 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27342689  }}</ref>


=== '''Padova classification''' ===
=== '''Padova classification''' ===
{| class="wikitable"
{| class="wikitable"
|-
|-
|'''1.  Negative for dysplasia'''
|'''1.  Negative for [[dysplasia]]'''
1.0  Normal
1.0  Normal


Line 24: Line 24:
1.2.2  IM Incomplete type
1.2.2  IM Incomplete type
|-
|-
|'''2.  Indefinite for dysplasia'''
|'''2.  Indefinite for [[dysplasia]]'''


2.1  Foveolar hyperproliferation
2.1  Foveolar hyperproliferation
Line 36: Line 36:
3.2  High-grade
3.2  High-grade


3.2.1  Including suspicious for [[carcinoma]] without invasion (intreglandular)
3.2.1  Including suspicious for [[carcinoma]] without [[invasion]] (interglandular)


3.2.2  Including [[carcinoma]] without invasion (intraglandular)
3.2.2  Including [[carcinoma]] without invasion (intraglandular)
Line 51: Line 51:
|-
|-
|Group I
|Group I
|Normal [[mucosa]] and [[benign]] lesions with no [[atypia]]
|Normal [[mucosa]] and [[benign]] [[lesions]] with no [[atypia]]
|-
|-
|Group II
|Group II
|Lesions showing [[atypia]] but diagnosed as [[benign]] (non-[[Neoplastic disease|neoplastic]])
|[[Lesions]] showing [[atypia]] but diagnosed as [[benign]] (non-[[Neoplastic disease|neoplastic]])
|-
|-
|Group III
|Group III
|Borderline lesions between [[benign]] and [[malignant]]
|Borderline [[lesions]] between [[benign]] and [[malignant]]
|-
|-
|Group V
|Group V
|Lesions strongly suspected of [[carcinoma]]
|[[Lesions]] strongly suspected of [[carcinoma]]
|-
|-
|Group V
|Group V

Revision as of 17:43, 14 January 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2] Mohammed Abdelwahed M.D[3]

Stomach cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stomach Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Endoscopy and Biopsy

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Stomach cancer classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stomach cancer classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stomach cancer classification

CDC on Stomach cancer classification

Stomach cancer classification in the news

Blogs on Stomach cancer classification

Directions to Hospitals Treating Stomach cancer

Risk calculators and risk factors for Stomach cancer classification

Overview

Gastric cancer can be classified according to the Padova classification system based upon the grade of metaplasia, dysplasia and invasiveness of the disease. It may also be classified according to the Japanese classification system based on the type of lesions (benign or malignant) and atypia.

Classification

Gastric cancer can be classified according to the Padova classification system based upon the grade of metaplasia, dysplasia and invasiveness of the disease. It may also be classified according to the Japanese classification system based on the type of lesions (benign or malignant) and atypia. The following tables briefly outline the major classification systems:[1][2]

Padova classification

1. Negative for dysplasia

1.0 Normal

1.1 Reactive foveolar hyperplasia

1.2 Intestinal metaplasia (IM)

1.2.1 IM Complete type

1.2.2 IM Incomplete type

2. Indefinite for dysplasia

2.1 Foveolar hyperproliferation

2.2 Hyperproliferative IM

3. Non-invasive neoplasia (flat or elevated [synonym adenoma])

3.1 Low-grade

3.2 High-grade

3.2.1 Including suspicious for carcinoma without invasion (interglandular)

3.2.2 Including carcinoma without invasion (intraglandular)

4. Suspicious for invasive carcinoma
5. Invasive adenocarcinoma

Japanese classification

Category Definition
Group I Normal mucosa and benign lesions with no atypia
Group II Lesions showing atypia but diagnosed as benign (non-neoplastic)
Group III Borderline lesions between benign and malignant
Group V Lesions strongly suspected of carcinoma
Group V Carcinoma

References

  1. Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K; et al. (2000). "Gastric dysplasia: the Padova international classification". Am J Surg Pathol. 24 (2): 167–76. PMID 10680883.
  2. Japanese Gastric Cancer Association (2017). "Japanese gastric cancer treatment guidelines 2014 (ver. 4)". Gastric Cancer. 20 (1): 1–19. doi:10.1007/s10120-016-0622-4. PMC 5215069. PMID 27342689.

Template:WH Template:WS